EXOZ · eXoZymes Inc.
What's happening
- EXOZ is up 23.50% today, trading at $4.94. — Live quote
- Volume today (212) is well below its 3-month average of 9,320. (Finnhub fundamentals)
- Reports earnings on 2026-11-09, 18 days away. (Finnhub earnings calendar)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $75.3M | $61.4M | $45.1M | $27.8M | $28.4M |
| P/E | -7.61 | -6.92 | -5.53 | -3.85 | -4.83 |
| Price/Book | 20.60 | 40.16 | 8.40 | 3.85 | 3.20 |
| ROE | -270.82% | -580.72% | -151.83% | -99.97% | -66.22% |
| ROA | -123.98% | -220.81% | -105.71% | -74.75% | -51.03% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
Not enough positive evidence under the current rules.
Potential concerns
- Latest SEC filing is Form 4, filed 2026-10-19; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on EXOZ
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$3.0M | -$2.4M | -$2.5M | -$2.5M | -$2.0M | -$1.6M | -$1.3M | -$1.0M |
| Net income | -$2.9M | -$2.4M | -$2.3M | -$2.4M | -$1.9M | -$1.7M | -$1.4M | -$1.0M |
| EPS (diluted) | $-0.33 | $-0.28 | $-0.27 | $-0.28 | $-0.22 | $-0.27 | $-0.22 | $-0.16 |
| EPS (basic) | $-0.33 | $-0.28 | $-0.27 | $-0.28 | $-0.22 | $-0.27 | $-0.22 | $-0.16 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $8.0M | $4.0M | $6.0M | $7.7M | $9.7M | $11.5M | $13.0M | $3.6M |
| Total liabilities | $4.3M | $2.5M | $2.6M | $2.3M | $2.4M | $2.6M | $2.6M | $7.2M |
| Stockholders' equity | $3.7M | $1.5M | $3.4M | $5.4M | $7.2M | $8.9M | $10.4M | -$3.6M |
| Total current assets | $6.2M | $2.1M | $3.9M | $5.6M | $7.5M | $9.4M | $10.8M | $1.4M |
| Total current liabilities | $1.6M | $1.6M | $1.6M | $1.2M | $1.2M | $1.4M | $1.3M | $5.8M |
| Cash & equivalents | $5.7M | $1.4M | $3.0M | $5.1M | $7.0M | $8.5M | $9.7M | $233.9K |
| Property, plant & equipment | $670.9K | $747.9K | $764.4K | $763.0K | $821.3K | $843.0K | $882.4K | $739.6K |
| Accounts payable | $1.3M | $1.2M | $1.2M | $904.4K | $930.6K | $1.1M | $924.3K | $908.6K |
| Other current liabilities | — | $13.4K | $5.3K | $17.1K | — | $135.7K | $179.0K | — |
| Common stock & paid-in capital | $9 | $8 | $8 | $8 | $8 | $8 | $8 | $6 |
| Retained earnings | -$26.4M | -$23.5M | -$21.1M | -$18.4M | -$16.2M | -$13.8M | -$11.9M | -$10.1M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.6M | -$1.5M | -$2.0M | -$1.9M | -$1.5M | -$1.1M | -$5.7M | -$541.5K |
| Investing cash flow | $1 | -$57.6K | -$75.0K | -$13.3K | -$30.9K | -$31.0K | -$210.4K | $30.9K |
| Financing cash flow | $5.8M | -$12.7K | -$10.6K | $26.1K | — | -$43.3K | $15.4M | $586.4K |
| Free cash flow | -$1.6M | -$1.6M | -$2.0M | -$1.9M | -$1.6M | -$1.2M | -$5.9M | -$541.5K |
| Capital expenditures | -$1 | $57.6K | $75.0K | $13.3K | $50.6K | $31.0K | $210.4K | $0 |
| Share-based compensation | $1.2M | $501.1K | $677.9K | $425.7K | $567.3K | $317.3K | $317.3K | $317.3K |
| Change in accounts receivable | -$101.6K | -$214.5K | $214.7K | $45.2K | -$337.8K | -$142.1K | $183.3K | -$593.2K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Revenue | — | — | $70.1K |
| Operating income | -$9.7M | -$5.9M | -$1.8M |
| Net income | -$9.2M | -$5.9M | -$2.0M |
| EPS (diluted) | $-1.09 | $-0.89 | $-0.33 |
| EPS (basic) | $-1.09 | $-0.89 | $-0.33 |
| Operating margin | — | — | -$2.6K |
| Net margin | — | — | -$2.9K |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 |
|---|---|---|---|---|
| Total assets | $6.0M | $13.0M | $3.6M | — |
| Total liabilities | $2.6M | $2.6M | $3.9M | — |
| Stockholders' equity | $3.4M | $10.4M | -$384.3K | $1.4M |
| Total current assets | $3.9M | $10.8M | $1.2M | — |
| Total current liabilities | $1.6M | $1.3M | $2.4M | — |
| Cash & equivalents | $3.0M | $9.7M | $66.5K | — |
| Property, plant & equipment | $764.4K | $882.4K | $753.4K | — |
| Accounts payable | $1.2M | $924.3K | $702.9K | — |
| Other current liabilities | $5.3K | $179.0K | $445.1K | — |
| Common stock & paid-in capital | $8 | $8 | $6 | — |
| Retained earnings | -$21.1M | -$11.9M | -$6.1M | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Operating cash flow | -$6.5M | -$8.5M | -$1.2M |
| Investing cash flow | -$150.2K | -$359.2K | -$311.2K |
| Financing cash flow | -$27.7K | $18.5M | $1.0M |
| Free cash flow | -$6.7M | -$8.9M | -$1.5M |
| Capital expenditures | $169.9K | $396.5K | $288.7K |
| Share-based compensation | $2.0M | $1.1M | $281.5K |
| Change in accounts receivable | -$219.9K | -$145.0K | $72.8K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding EXOZ as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2024-11-08 to 2026-08-26
Recent transactions
- Insiders have net bought 855 shares over the last 182 days, across 5 purchases and 0 sales.
- Most recent: Heltzen Michael (Chief Executive Officer) — Open market purchase of 4 shares on 2026-08-26.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Heltzen Michael | Chief Executive Officer | Open market purchase | 2026-08-26 | 4 |
| Perriman Damien Alan | Chief Commercial Officer | Option exercise | 2026-08-19 | 19,612 |
| Korman Tyler Paz | Chief Scientific Officer | Option exercise | 2026-08-19 | 32,964 |
| Opgenorth Paul Hideo | Vice President, Development | Grant / award | 2026-04-01 | 3,999 |
| Nawaz Fouad | Vice President- Finance | Grant / award | 2026-04-01 | 5,999 |
| MDB Capital Holdings, LLC | 10% owner | Derivative conversion | 2024-11-08 | 122,657 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-26 | Heltzen Michael | Chief Executive Officer | Open market purchase | 4 | $7.58 |
| 2026-08-26 | Heltzen Michael | Chief Executive Officer | Open market purchase | 251 | $7.35 |
| 2026-08-26 | Heltzen Michael | Chief Executive Officer | Open market purchase | 250 | $7.60 |
| 2026-08-25 | Heltzen Michael | Chief Executive Officer | Open market purchase | 250 | $7.52 |
| 2026-08-25 | Heltzen Michael | Chief Executive Officer | Open market purchase | 100 | $7.50 |
| 2026-08-19 | Heltzen Michael | Chief Executive Officer | Grant / award | 8,841 | $6.40 |
| 2026-08-19 | Perriman Damien Alan | Chief Commercial Officer | Option exercise | 19,612 | — |
| 2026-08-19 | Korman Tyler Paz | Chief Scientific Officer | Option exercise | 32,964 | — |
| 2026-04-09 | Korman Tyler Paz | Chief Scientific Officer | Open market sale | 750 | $10.53 |
| 2026-04-08 | Korman Tyler Paz | Chief Scientific Officer | Open market sale | 750 | $10.04 |
| 2026-04-01 | Perriman Damien Alan | Chief Commercial Officer | Grant / award | 62,759 | $0.00 |
| 2026-04-01 | Perriman Damien Alan | Chief Commercial Officer | Grant / award | 8,887 | $8.44 |
| 2026-04-01 | Opgenorth Paul Hideo | Vice President, Development | Grant / award | 3,999 | $8.44 |
| 2026-04-01 | Nawaz Fouad | Vice President- Finance | Grant / award | 5,999 | $8.44 |
| 2026-04-01 | Korman Tyler Paz | Chief Scientific Officer | Grant / award | 5,332 | $8.44 |
| 2025-07-02 | Heltzen Michael | Chief Executive Officer | Open market purchase | 1,040 | $10.22 |
| 2025-06-16 | Korman Tyler Paz | Vice President, Research | Grant / award | 2,990 | $12.54 |
| 2025-06-13 | Opgenorth Paul Hideo | Vice President, Development | Grant / award | 2,990 | $12.54 |
| 2025-06-13 | Nawaz Fouad | Vice President, Finance | Grant / award | 3,489 | $12.54 |
| 2025-01-17 | Heltzen Michael | Chief Executive Officer | Open market purchase | 1,767 | $10.78 |
| 2025-01-16 | Heltzen Michael | Chief Executive Officer | Open market purchase | 121 | $10.72 |
| 2024-11-15 | Heltzen Michael | Chief Executive Officer | Open market purchase | 1,984 | $11.10 |
| 2024-11-08 | Opgenorth Paul Hideo | Vice President, Development | Derivative conversion | 2,344 | $6.40 |
| 2024-11-08 | MDB Capital Holdings, LLC | 10% owner | Derivative conversion | 122,657 | $6.40 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 08:39 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-19 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-10-19 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-10-19 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-10-19 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-10-19 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-10-19 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-10-09 | 8-K | 2026-10-09 | View on SEC.gov → |
| 2026-09-18 | 8-K | 2026-09-17 | View on SEC.gov → |
| 2026-09-17 | 4 | 2026-09-14 | View on SEC.gov → |
| 2026-09-02 | 4 | 2026-08-19 | View on SEC.gov → |
| 2026-08-25 | 4 | 2026-08-19 | View on SEC.gov → |
| 2026-08-25 | 4 | 2026-08-19 | View on SEC.gov → |
Recent news
Headlines about EXOZ (eXoZymes Inc.). Links open the publisher — we don’t host full articles.
-
eXoZymes CEO to Discuss Commercialization, Key Milestones, and Potential Catalysts in Fireside Chat with Water Tower Research
Yahoo · 2026-10-21 -
A rare natural molecule is central to eXoZymes' plans for supplements
Stock Titan · 2026-10-21 -
Form 4 eXoZymes Inc: Tyler Paz Korman (Chief Scientific Officer) For: 19 August
Investing.com UK · 2026-10-21 -
Exozymes Inc. Director Edgardo Rayo Granted 25,000 Stock Options at $6.28 Exercise Price
Kalkine Media · 2026-10-20 -
Exozymes Inc. Director James Joseph Lalonde Granted 10,000 Stock Options
Kalkine Media · 2026-10-20 -
A director receives 25,000 Exozymes (EXOZ) stock options with a $6.28 exercise price.
Stock Titan · 2026-10-19 -
Options for 10,000 shares at $6.28 go to Exozymes (EXOZ) director Marlett.
Stock Titan · 2026-10-19 -
A director receives a 10,000-share option from ExoZymes (EXOZ), with a $6.28 exercise price.
Stock Titan · 2026-10-19
No headlines in this category right now — try “All”.